← All trials
NCT04544787
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 22, 2018
- Primary completion
- Jan 31, 2019
- Completion date
- May 8, 2019
- First posted
- Sep 10, 2020
- Last posted
- Sep 10, 2020
- Enrollment
- 250
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of AntwerpLead sponsor
- PATHCollaborator
- University of AntwerpSponsor investigator
- Centers for Disease Control and Prevention (CDC)Collaborator
- CelerionCollaborator
- Bill and Melinda Gates FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.